The use of glycosylation and ubiquitin-like modifications such as SUMOylation and neddylation in AAV2 vectors increases the efficiency of transduction in vivo and increases the expression level of factor IX (up to 2-fold) in a mouse model of hemophilia B [72,73]. Here, F9 is linked to hemophilia B.